Your English writing platform
Discover LudwigSuggestions(1)
Exact(8)
The genetically engineered, humanized anti-CD33 antibody HuM195 has demonstrated modest activity against overt relapsed acute myeloid leukemia (AML) and more substantial activity against minimal residual disease in acute promyelocytic leukemia.
Administration of platinum-based chemotherapy in first-line non-small cell lung cancer (NSCLC) has demonstrated modest improvements in overall survival (OS).
Although lapatinib has demonstrated modest activity in this setting, trials reported to date have yet to demonstrate improvements in overall survival with its use.
A phase III trial has demonstrated modest benefit for trastuzumab and vinorelbine plus the FDA-approved mTOR inhibitor everolimus in patients with trastuzumab-insensitive, HER2-positive MBC.
This phase II trial has demonstrated modest activity of the combination of gemcitabine and capecitabine in a population of patients with immunotherapy-refractory metastatic renal carcinoma.
Lapatinib has demonstrated modest clinical activity in this setting and highlights the importance of ongoing HER2 blockade in trastuzumab-refractory states.
Similar(52)
Similarly, a number of studies have demonstrated modest improvements in gastrointestinal perfusion with fluid resuscitation [73]; however, this finding is not consistent in all the animal studies [74].
Multiple landmark clinical trials have demonstrated modest renoprotection with statins [ 13].
Importantly the findings have demonstrated modest but significant effect sizes [ 10].
Low-intensity counseling trials (≤ 30 minutes/year) have demonstrated modest diet changes, but no improvement in lipids.
Several clinical reports have demonstrated modest reduction in mitochondrial complex I activity in PD patients [ 41, 42].
Write better and faster with AI suggestions while staying true to your unique style.
Since I tried Ludwig back in 2017, I have been constantly using it in both editing and translation. Ever since, I suggest it to my translators at ProSciEditing.

Justyna Jupowicz-Kozak
CEO of Professional Science Editing for Scientists @ prosciediting.com